PubMed
Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet
Leffler et al., 2015
Healing & RecoveryInvestigationalS
Larazotide
AT-1001
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 2
- Research grade
- S
- Community score
- 69
- Trackers
- 1,415
Trend index
Overview
About Larazotide
Tight-junction regulator peptide studied for gut barrier and celiac-associated symptoms.
- Category
- Healing & Recovery
- Regulatory status
- Investigational
- Also known as
- AT-1001
- Self-reports
- 6
Community
What 6 users report
6 community reports
Positive 0% · Neutral 100% · Negative 0%
Most reported benefits
Recovery
6
Most reported side effects
Digestive upset
6
Dose distribution
Median: 1000–2000 mcg · Most common: 1000–2000 mcg
0–25
0
25–50
0
50–100
0
100–200
0
200–400
0
400–600
0
600–1000
0
1000–2000
3
2000+
3
Commonly stacked with
Research
Cited research (1)
Source
Help
Frequently asked
What do PeptIQ users report about Larazotide?
This page summarizes 6 anonymized self-reports from PeptIQ users who track Larazotide, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
What research is cited for Larazotide?
1 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is Larazotide safe to use?
This wiki does not assess safety or recommend use. Larazotide is listed as Investigational. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of Larazotide?
Research, primarily in animal models, suggests Larazotide may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of Larazotide?
Larazotide is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified Larazotide as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of Larazotide?
The safety and effectiveness of Larazotide have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on Larazotide?
While there are over 200 published studies on Larazotide, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source